

40년 전통의 제약 제조 사업



MERGERSCORP

40

이 회사는 1982년 인도 펀자브 지역에서 활성 의약품 원료 제조를 목적으로 설립되었습니다.

이 회사는 제약업계의 여러 선도 기업을 위해 원료를 제조하는 원료의약품(API) 제조 회사로, 이 제품을 사용하여 의약품을 제조합니다.

Pfizer, Abbott, Cipla, Glenmark, Macleods, Aristo 등의 회사에 제품을 공급합니다.

이 회사는 항생제, 비타민, 항응고제부터 안과용 제품까지 다양한 제품을 제공하고 있습니다. 또한 인도 및 해외 규제 기관의 ISO, ZED, GMP 등 여러 기관에서 비즈니스 감사를 받습니다.

비즈니스는 새로운 표적 치료에 효과가 있으면서도 부작용이 없는 재조합 단백질에 대한 특허 기술을 개발 중입니다. 현재 운영은 하이엔드 신규 분자에 중점을 두고 있습니다.

연구

회사는 현재 부작용이 없는 약물의 미래를 약속하는 줄기세포 회춘 치료법에 대한 실험 연구를 진행하고 있습니다.

생명공학

이 회사는 표적 인간 치료 단백질 분야에서 중요한 생명공학 연구 활동을 수행하고 있습니다. 현재 천식과 알레르기 환자를 치료하는 동시에 비만세포증과 호염기성 백혈병에도 효과가 있는 신약을 개발하는 데 중점을 두고 연구하고 있습니다.

팀

이 팀은 화학자, 약사, 생명공학자, 품질 관리자, R&D 전문가, 창고 담당자 등 100명의 계몽된 개인으로 구성되어 있습니다.

인도 65% / 기타 국가/유럽 35%

25개 OEM 제품 / 제약 활성 성분 원료

: 항생제

ISO9001, EU 표준(FDA 없음)

: 20%+/년

100명 이상의 직원

TARGET PRICE

\$40,000,000

GROSS REVENUE

\$25,000,000

EBITDA

\$3,000,000

BUSINESS TYPE

제약

ESTABLISHED

1989

SUPPORT & TRAINING

12 개월

REASON FOR SELLING

퇴직

COUNTRY

인도

BUSINESS ID

L#20210013

화학 엔지니어 배경

2,500만 달러 매출 / 300만 달러 EBITDA

고객:



The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM